News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sention Inc. To Develop Novel Merck & Co., Inc. (MRK) Compounds For Mental Retardation, Sention Secures Access To Potential New Product


10/19/2005 5:12:24 PM

PROVIDENCE, R.I.--(BUSINESS WIRE)--Jan. 19, 2005--Sention Inc. today announced that it has entered into an exclusive licensing and research collaboration agreement with Merck & Co., Inc. (NYSE: MRK) to develop a family of Merck compounds known as mGluR5 antagonists as potential treatments for Fragile X mental retardation. Fragile X is the most commonly inherited form of mental retardation.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES